Zonisamide improves motor function in Parkinson disease

@article{Murata2007ZonisamideIM,
  title={Zonisamide improves motor function in Parkinson disease},
  author={Miho Murata and Kazuko Hasegawa and Ichiro Kanazawa},
  journal={Neurology},
  year={2007},
  volume={68},
  pages={45 - 50}
}
Objective: To evaluate the efficacy, safety and tolerability of daily doses of 25, 50, and 100 mg of zonisamide (ZNS) administered as adjunctive treatment in patients with Parkinson disease (PD). Methods: We conducted a multicenter, randomized, double-blind, parallel-treatment, placebo-controlled study in Japan. Patients with PD who showed insufficient response to levodopa treatment were given placebo for 2 weeks and then treated for 12 weeks with 25, 50, or 100 mg/day of ZNS or placebo, in… Expand
View on Wolters Kluwer
ncbi.nlm.nih.gov
139 Citations
Highly Influential Citations
5
Background Citations
19
Methods Citations
1
Results Citations
1

139 Citations

Citation Type

Citation Type

Adjunct zonisamide to levodopa for DLB parkinsonism
TLDR
This study provides Class I evidence that zonisamide (adjunctive to levodopa) improves parkinsonism and is well-tolerated in patients with DLB. Expand
Zonisamide: in Parkinson's disease.
TLDR
Zonisamide 25 mg once daily as adjunctive therapy with levodopa was generally well tolerated by patients with Parkinson's disease and was associated with increased striatal dopamine levels in animal models. Expand
Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials
TLDR
The findings indicate that zonisamide improved parkinsonism with DLB without deterioration of cognitive function and or worsening behavioral and psychological symptoms of dementia. Expand
Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial.
TLDR
Daily administration of 25- or 50-mg zonisamide significantly improved motor function compared with placebo; both doses were safe and well tolerated in patients with DLB. Expand
Zonisamide for the treatment of Parkinson’s disease
  • H. Miwa
  • Medicine
  • Expert review of neurotherapeutics
  • 2007
TLDR
It is expected that zonisamide will be safe and tolerated in patients with PD, as it has been used as an antiepileptic for more than 15 years; however, further studies are required to evaluate its safety and tolerability in the treatment of PD. Expand
The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data
TLDR
Zonisamide significantly improved the Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) without affecting the Mini-Mental State Examination (MMSE) or Neuropsychiatry Inventory-10 (NPI-10) scores at week 12. Expand
Zonisamide for Essential Tremor
  • W. Ondo
  • Medicine
  • Clinical neuropharmacology
  • 2007
TLDR
Zonisamide significantly (albeit modestly) improved the TSGRS scores in this small group of medically refractory subjects who completed the evaluation, however, clinical impressions did not improve, and the study was complicated by a large dropout rate caused by subjective lack of efficacy and by AEs. Expand
Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial
TLDR
Zonisamide may be safe and effective for the treatment of tardive dyskinesia associated with antipsychotic treatment and these preliminary findings need to be further explored by larger well-designed trials. Expand
Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
TLDR
As an adjunct to levodopa, rasagiline reduced OFF-time and improved PD symptoms/signs (MDS-UPDRS scores) and quality of life in Japanese patients with PD and wearing-off phenomena. Expand
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
TLDR
As an adjunct to l-DOPA, safinamide safely increased ON-time and improved PD symptoms/signs in PD patients with wearing-off. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
TLDR
Once-daily rasagiline reduces mean daily off-time and improves symptoms of Parkinson's disease in levodopa-treated patients with motor fluctuations, an effect similar to that of entacapone. Expand
Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.
  • M. Murata
  • Medicine
  • Current pharmaceutical design
  • 2004
TLDR
It is suggested that the activation of dopamine synthesis and the moderate level of MAOB inhibition are main mechanisms of ZNS effects on PD. Expand
Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol.
TLDR
Although the number of enrolled patients was limited, this open-label pilot study suggests that ZNS may have a therapeutic potential for essential tremor and a controlled trial of this drug in the future would be valuable. Expand
Zonisamide has beneficial effects on Parkinson's disease patients
TLDR
It is speculated that long lasting activation of dopamine synthesis by ZNS ameliorates parkinsonian symptoms, in particular wearing-off. Expand
Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.
TLDR
This study confirms that a continuous levodopa infusion is associated with reduced motor complications compared with the standard oral formulation of the drug in patients with advanced PD. Expand
Randomized, double‐blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease
We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to… Expand
Effects of zonisamide on dopaminergic system
TLDR
It is suggested that therapeutic ZNS doses increase DOPA accumulation as well as both intracellular and extracellular DA, DOPA and HVA levels, and that acute and chronic supratherapeutic ZNS dose administrations inhibit DA turnover. Expand
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson’s activity
TLDR
Results support previously reported findings and provide additional evidence that the anticonvulsant ZNS appears to possess anti-Parkinson’s properties and could be a novel agent for the treatment of PD that could delay the use of or reduce the amount of levodopa needed to treat patients with PD. Expand
Effects of zonisamide on extracellular levels of monoamine and its metabolite, and on Ca2+ ependent dopamine release
TLDR
The present results suggest that zonisamide facilitates dopaminergic and serotoninergic neurotransmission but does not affect Ca2+ dependent dopamine release within therapeutic plasma concentrations. Expand
Mechanisms of T-type calcium channel blockade by zonisamide
TLDR
The blockade of T-type calcium channels by zonisamide could suppress an important component of inward current that underlies epileptiform cellular bursting, thereby inhibiting the spread of seizure activity. Expand
...
1
2
...